http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-302282-B6
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2901e694724c2a759f619944cb7d2a4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1034 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate | 2000-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc7f97822a2b7112ea395cb7d89f26e6 |
| publicationDate | 2011-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-302282-B6 |
| titleOfInvention | A method of preparing adenovirus and a kit for studying therapeutically effective compounds |
| abstract | The invention relates to a process for the preparation of an adenovirus, comprising a) preparing a first plasmid called a shuttle plasmid, preferably a prokarytotic plasmid, comprising a first truncated recombinant adenoviral genome comprising at least one heterologous nucleic acid, b) contacting the first plasmid with a second plasmid called a parent plasmid a second truncated recombinant adenoviral genome that is complementary to the genome of the first plasmid, wherein both plasmids are in cyclic form, and allowing homologous recombination to produce a terminal plasmid containing the complete recombinant adenoviral genome, and c) cleaving the complete linear recombinant adenovirus genome from the terminal plasmid into an encapsidation line to produce recombinant adenoviruses containing the full-length recombinant adenoviral genome, wherein both the shuttle plasmid and the parental plasmids d contain an identical adenoviral homologous region, both of which contain an origin of replication and a different selection marker for the selection of each member, and both plasmids contain an ITR flanked by a restriction site not present in the adenoviral genome, and one or the other plasmid contains an encapsidation sequence study of therapeutically effective compounds. |
| priorityDate | 1999-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 231.